{"created":"2023-06-20T14:35:06.961507+00:00","id":553,"links":{},"metadata":{"_buckets":{"deposit":"da3fd4fa-7554-49e2-b0b1-73c141bd2d18"},"_deposit":{"created_by":15,"id":"553","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"553"},"status":"published"},"_oai":{"id":"oai:kjunshin.repo.nii.ac.jp:00000553","sets":["1:99"]},"author_link":["910"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-04","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"12","bibliographicPageStart":"1","bibliographicVolumeNumber":"24","bibliographic_titles":[{"bibliographic_title":"鹿児島純心女子大学看護栄養学部紀要"},{"bibliographic_title":"Bulletin of Faculty of Nursing and Nutrition, Kagoshima Immaculate Heart University","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"パーキンソン病でドパミンが減少していることが発見され,ドパミン補充療法が臨床応用されてから50年近くたった。日本では1972年にL-DOPA単剤(http://www.info.pmda.go.jp/go/pack/1164001B1034_1_09/)が,1980年にDCIとの合剤(http://www.info.pmda.go.jp/go/pack/1169100F1052_1_10/)が販売開始された。現在までパーキンソン病やドパミンに関して,様々なことが明らかになったが,治療としては依然,ドパミン補充療法がゴールドスタンダードであり続けている。iPS細胞が発見されてから,パーキンソン病の新たな対症療法として利用できるのではないかという研究が急ピッチで進んでいる。パーキンソン病は全身疾患であるので,脳内にドパミン神経細胞を移植しても脳内特異的なドパミン補充療法と何ら変わることはない。以前より行われている胎児脳の移植と同じである。胎児脳を移植された患者は,dyskinesiaに苦しんだ(Ma et al, 2002)。更に,L-DOPAが効く軽症な患者にのみ移植治療は有効であり(森島, 2019),メリットはない。パーキンソン病の患者管理は医療保険整備等のおかげで随分良くなっており,その平均寿命は健常者とほぼ同じである(http://www.nanbyou.or.jp/entry/169)。L-DOPAは発症初期にはよく効き,ハネムーンピリオドと言われる。効果が減弱して死亡するまでの期間のADLをどう保たせるかが臨床医の最大の懸案である。ドパミンが伝達物質として確立されてから70年が経つが,ドパミンの機能について未だ明らかになっていないことも多い。最近のパーキンソン病に関するモノグラフは神経再生治療や遺伝子に関したものばかりでドパミン伝達に関したものは殆どない。2010年の発行で少し古いが,ドパミンに関した英文モノグラフを見つけた。そこで,それを参考とし,また,自身の関連した研究も再考することにより地道にドパミンのことを勉強し直して,少しでもハネムーンピリオドが過ぎ去った後のパーキンソン病患者のADLを維持する方法を見出したいと考え執筆した。(著者抄録)","subitem_description_type":"Abstract"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1348-4303","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"岩田, 真一","creatorNameLang":"ja"},{"creatorName":"イワタ, シンイチ","creatorNameLang":"ja-Kana"}],"familyNames":[{"familyName":"岩田","familyNameLang":"ja"},{"familyName":"イワタ","familyNameLang":"ja-Kana"}],"givenNames":[{"givenName":"真一","givenNameLang":"ja"},{"givenName":"シンイチ","givenNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"910","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"9000000439080","nameIdentifierScheme":"CiNii ID","nameIdentifierURI":"http://ci.nii.ac.jp/nrid/9000000439080"},{"nameIdentifier":"60253861","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=60253861"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-01-22"}],"displaytype":"detail","filename":"パーキンソン病とドバミン.pdf","filesize":[{"value":"15.0 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"パーキンソン病とドバミン","url":"https://kjunshin.repo.nii.ac.jp/record/553/files/パーキンソン病とドバミン.pdf"},"version_id":"10d62ec4-be61-4655-865f-5732cff4394e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"*Dopamine(欠損・欠乏)","subitem_subject_scheme":"Other"},{"subitem_subject":"In Situ Hybridization","subitem_subject_scheme":"Other"},{"subitem_subject":"Levodopa(治療的利用,毒性・副作用)","subitem_subject_scheme":"Other"},{"subitem_subject":"mRNA","subitem_subject_scheme":"Other"},{"subitem_subject":"シグナルトランスダクション","subitem_subject_scheme":"Other"},{"subitem_subject":"Tyrosine 3-Monooxygenase","subitem_subject_scheme":"Other"},{"subitem_subject":"Adrenergic Beta-Antagonists(治療的利用)","subitem_subject_scheme":"Other"},{"subitem_subject":"ジスキネジア-薬物性","subitem_subject_scheme":"Other"},{"subitem_subject":"逆行変性","subitem_subject_scheme":"Other"},{"subitem_subject":"Dopamine Receptors","subitem_subject_scheme":"Other"},{"subitem_subject":"神経再生","subitem_subject_scheme":"Other"},{"subitem_subject":"神経終末","subitem_subject_scheme":"Other"},{"subitem_subject":"振戦(病因,薬物療法)","subitem_subject_scheme":"Other"},{"subitem_subject":"線条体","subitem_subject_scheme":"Other"},{"subitem_subject":"*Parkinson病(合併症,薬物療法,実験的)","subitem_subject_scheme":"Other"},{"subitem_subject":"Dopamine Agonists(治療的利用,毒性・副作用)","subitem_subject_scheme":"Other"},{"subitem_subject":"痛覚","subitem_subject_scheme":"Other"},{"subitem_subject":"生理学的フィードバック","subitem_subject_scheme":"Other"},{"subitem_subject":"組織マイクロアレイ法","subitem_subject_scheme":"Other"},{"subitem_subject":"ドーパミン作動性ニューロン","subitem_subject_scheme":"Other"},{"subitem_subject":"RNA-Seq解析","subitem_subject_scheme":"Other"},{"subitem_subject":"ヒト","subitem_subject_scheme":"Other"},{"subitem_subject":"マウス","subitem_subject_scheme":"Other"},{"subitem_subject":"ラット","subitem_subject_scheme":"Other"},{"subitem_subject":"動物","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"パーキンソン病とドパミン","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"パーキンソン病とドパミン"}]},"item_type_id":"10002","owner":"15","path":["99"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-01-22"},"publish_date":"2022-01-22","publish_status":"0","recid":"553","relation_version_is_last":true,"title":["パーキンソン病とドパミン"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2023-10-19T09:24:29.557285+00:00"}